These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25061430)

  • 21. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
    Degli Esposti L; Piccinni C; Sangiorgi D; Perrone V; Aledda L; Marrosu MG; Lombardo F
    Neurol Sci; 2017 Apr; 38(4):589-594. PubMed ID: 28078563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
    Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
    Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
    Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
    Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform.
    Jokubaitis VG; Spelman T; Lechner-Scott J; Barnett M; Shaw C; Vucic S; Liew D; Butzkueven H; Slee M;
    PLoS One; 2013; 8(3):e59694. PubMed ID: 23527252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population.
    Molazadeh N; Sahraian MA; Ghajarzadeh M
    Caspian J Intern Med; 2023; 14(1):89-93. PubMed ID: 36741493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment selection and experience in multiple sclerosis: survey of neurologists.
    Hanson KA; Agashivala N; Wyrwich KW; Raimundo K; Kim E; Brandes DW
    Patient Prefer Adherence; 2014; 8():415-22. PubMed ID: 24729689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
    Hendin B; Naismith RT; Wray SE; Huang D; Dong Q; Livingston T; Jones DL; Watson C; Jhaveri M
    Patient Prefer Adherence; 2018; 12():1289-1297. PubMed ID: 30050291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
    Lampl C; You X; Limmroth V
    Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.
    Moses H; Brandes DW
    Curr Med Res Opin; 2008 Sep; 24(9):2679-90. PubMed ID: 18694542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
    Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
    Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.